We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$326M
AUM Growth
+$72.3M
Cap. Flow
-$3.11M
Cap. Flow %
-0.95%
Top 10 Hldgs %
66.65%
Holding
46
New
15
Increased
5
Reduced
6
Closed
15

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$13.7M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.7M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.71M
4
DERM
Dermira, Inc.
DERM
+$8.05M
5
KA
Kineta, Inc. Common Stock
KA
+$8M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$21.8M
2
CYTK icon
Cytokinetics
CYTK
+$13.5M
3
XLRN
Acceleron Pharma
XLRN
+$12.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.51M
5
EPZM
Epizyme, Inc
EPZM
+$7.73M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Miscellaneous 20.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
26
DELISTED
Chimerix, Inc.
CMRX
$3.31M 1.02%
+598,062
New +$2.74M
OMED
27
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$3.04M 0.93%
+265,784
New +$3.09M
FATE icon
28
Fate Therapeutics
FATE
$291M
$1.84M 0.57%
+590,527
New +$1.43M
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$882K 0.27%
+6,360
New +$807K
CASC
30
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$170K 0.05%
+17,300
New +$123K
AKTX
31
Akari Therapeutics
AKTX
$20.8M
– –
-79
Closed -$856K
COLL icon
32
Collegium Pharmaceutical
COLL
$786M
– –
-281,776
Closed -$3.34M
EDIT icon
33
Editas Medicine
EDIT
$485M
– –
-85,469
Closed -$2.08M
ENTA icon
34
Enanta Pharmaceuticals
ENTA
$396M
– –
-136,882
Closed -$3.02M
TVTX icon
35
Travere Therapeutics
TVTX
$6.19B
– –
-1,225,084
Closed -$21.8M
XNCR icon
36
Xencor
XNCR
$1.94B
– –
-168,000
Closed -$3.19M
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-244,950
Closed -$9.51M
EIGR
38
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-473
Closed -$281K
IMGN
39
CALL
DELISTED
Immunogen Inc
IMGN
– –
-299,500
Closed -$922K
EPZM
40
DELISTED
Epizyme, Inc
EPZM
– –
-755,046
Closed -$7.73M
ADXS
41
DELISTED
Advaxis Inc
ADXS
– –
-6,187
Closed -$751K
XLRN
42
DELISTED
Acceleron Pharma
XLRN
– –
-371,381
Closed -$12.6M
FWP
43
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-12,047
Closed -$1.53M
ARRY
44
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-520,000
Closed -$1.85M
TSRO
45
DELISTED
TESARO, Inc.
TSRO
– –
-9,200
Closed -$773K
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2016 Portfolio in Review

As of Q3 2016, EcoR1 Capital held 46 positions worth $326M, up 28% from $254M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

EcoR1 Capital's Q3 2016 filing shows 15 new, 5 increased, 6 reduced and 15 closed positions. Its largest new stake was Ardelyx: 1,310,023 shares worth $17M. The largest sale was Travere Therapeutics, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2016 buy was Ardelyx: 1,310,023 shares worth $17M.
  • EcoR1 Capital added most to Dermira, Inc. in Q3 2016, an estimated $8.05M increase.
  • EcoR1 Capital's biggest Q3 2016 reduction was Cytokinetics, cutting an estimated $13.5M.
  • EcoR1 Capital fully exited Travere Therapeutics in Q3 2016, selling an estimated $21.8M.
  • EcoR1 Capital's ten largest holdings make up 67% of its $326M portfolio in Q3 2016.
  • EcoR1 Capital opened 15 new positions and closed 15 in Q3 2016.
  • EcoR1 Capital's portfolio value rose 28% quarter-over-quarter to $326M.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.